ライフサイエンスコーパス: cardiometabolic

1 h as aspirin, lipid-lowering mediations, and cardiometabolic agents.

2 < 0.001), while the summary effect size for cardiometabolic alterations was significantly lower than

3 ssed in NAFLD seem to differ with respect to cardiometabolic and antifibrotic efficacy, suggesting th

4 Cardiometabolic and demographic parameters associated wi

5 ge, were used to investigate associations of cardiometabolic and demographic parameters with reproduc

6 are consumed are of greater significance for cardiometabolic and general health than SFA intake alone

7 iated with negative health outcomes, such as cardiometabolic and neurodegenerative diseases.

8 istically contribute to modulate the risk of cardiometabolic and other non-communicable diseases thro

9 with HIV (PWH) to assess the association of cardiometabolic and other risk factors with cognitive im

10 middle-aged, predominantly male with similar cardiometabolic and psoriasis status between treatment g

11 nel study [A prospective Study COmparing the cardiometabolic and respiratory effects of air Pollution

12 Cardiometabolic and satiety hormonal profiles were deter

13 and non-CNS dysfunction (focusing on immune, cardiometabolic, and hypothalamic-pituitary-adrenal (HPA

14 A new cardiometabolic-based chronic disease (CMBCD) model is p

15 inable preventive care plan is described for cardiometabolic-based chronic disease.

16 ysia, combining nutritional assessments with cardiometabolic biomarkers defined by lipid, atherogenic

17 d joint associations of 25(OH)D and PTH with cardiometabolic biomarkers including high-sensitivity C-

18 Cardiometabolic biomarkers were collected in subpopulati

19 Cardiometabolic biomarkers were not significantly differ

20 However, the timing of the onset of cardiometabolic changes and the specific growth trajecto

21 Modern cardiometabolic clinical trials often include cardiovasc

22 In 9 cardiometabolic clinical trials with long-term follow-up

23 ith >=5.0% liver fat had the highest odds of cardiometabolic clustering (odds ratio 24.43 [95% confid

24 Cardiometabolic clustering was defined as having three o

25 Reproductive aging may contribute to cardiometabolic comorbid conditions.

26 on, but they may carry an increased risk for cardiometabolic comorbid conditions.

27 rategies that consider the increased risk of cardiometabolic comorbidities in patients with inflammat

28 Cardiometabolic comorbidities present a considerable bur

29 We propose here that sex differences in MDD-cardiometabolic comorbidity originate, in part, from pat

30 nt avenues for depression and its associated cardiometabolic comorbidity.

31 n light of these results, efforts to prevent cardiometabolic complications in PCOS should focus on wo

32 cal adaptations during pregnancy can provoke cardiometabolic complications or exacerbate existing car

33 siderable comorbidity between depression and cardiometabolic conditions (e.g., obesity, metabolic syn

34 Cardiometabolic conditions were common: 40.2% of women a

35 definition of multimorbidity including only cardiometabolic conditions, and participants were not re

36 g for demographics, lifestyle behaviors, and cardiometabolic conditions.

37 ng individuals with type 2 diabetes and good cardiometabolic control, women had worse myocardial perf

38 ciated with the largest numbers of estimated cardiometabolic deaths in 2010-12.

39 F) to estimate the proportional reduction in cardiometabolic deaths that would occur if exposure to e

40 Poor diet is a leading risk factor for cardiometabolic disease (CMD) in the United States, but

41 We utilized repeat measures of cardiometabolic disease (coronary heart disease, stroke,

42 and lipid classes previously associated with cardiometabolic disease (phosphatidylethanolamine and tr

43 rtic vascular inflammation and biomarkers of cardiometabolic disease after 52 weeks of treatment.

44 ohort study, we analysed data from the China Cardiometabolic Disease and Cancer Cohort Study, which r

45 he current variation in the global burden of cardiometabolic disease and emphasize the importance of

46 tus compounds the situation because both the cardiometabolic disease and its management might adverse

47 ng ancestral diversity in genetic studies of cardiometabolic disease and the challenges that arise fr

48 tabolic complications or exacerbate existing cardiometabolic disease and, conversely, how cardiometab

49 habit, as well as when participants without cardiometabolic disease at baseline were excluded from a

50 gating effects of fetal growth on later-life cardiometabolic disease because birth weight is only a c

51 bolites in Hispanics, a population with high cardiometabolic disease burden, is largely unknown.

52 cardiometabolic disease and, conversely, how cardiometabolic disease can compromise the adaptations t

53 tty liver disease is a major risk factor for cardiometabolic disease in adults.

54 between lower birthweight and higher risk of cardiometabolic disease in later life.

55 There is a growing burden of cardiometabolic disease in many parts of the world.

56 rategies that mitigate the growing burden of cardiometabolic disease in these communities.

57 airy products has been associated with lower cardiometabolic disease incidence.

58 or "sensitive" ages for later development of cardiometabolic disease is based on flawed methods for c

59 are "critical" or "sensitive" ages for later cardiometabolic disease is based on flawed methods for c

60 subtle forms of lipodystrophy contribute to cardiometabolic disease risk at a population level.

61 We used harmonised body mass index (BMI) and cardiometabolic disease risk factor data from 20,746 par

62 tion was examined in relation to a number of cardiometabolic disease risk factors collected in mid-ad

63 marize the effects of TRE on body weight and cardiometabolic disease risk factors in human subjects.

64 ed States during Lent had minimal effects on cardiometabolic disease risk factors.

65 ion was associated with worse values for all cardiometabolic disease risk factors.

66 9 kg/m2) includes adults with body shape and cardiometabolic disease risk features of excess adiposit

67 Abnorml birthweight is associated with cardiometabolic disease risk in adulthood; however, the

68 sistance and could be important mediators of cardiometabolic disease risk in women.

69 Cardiometabolic disease risk related to body shape in pe

70 scopy), and secondary outcomes as markers of cardiometabolic disease risk were assessed at baseline a

71 s Association risk score (AUC = 0.64), and a cardiometabolic disease system (using Adult Treatment Pa

72 Across a broad spectrum of subjects with cardiometabolic disease, a 32-single-nucleotide polymorp

73 etabolic responses to food influence risk of cardiometabolic disease, but large-scale high-resolution

74 stablished risk factor for later obesity and cardiometabolic disease, but the relative importance of

75 eral fat mass (VFM), a major risk factor for cardiometabolic disease, but their relative contribution

76 ean, 13.8; SD, 15.0), smoking, and prevalent cardiometabolic disease, individuals with the shortest-d

77 ing the populations who are most affected by cardiometabolic disease, to the aim of better understand

78 of the effect of autozygosity in 4 out of 13 cardiometabolic disease-associated traits using data fro

79 Healthier dietary habits are associated with cardiometabolic disease-free life expectancy between age

80 stigate the association of diet quality with cardiometabolic disease-free life expectancy between age

81 The association between diet quality and cardiometabolic disease-free life expectancy followed a

82 were used to estimate total and sex-specific cardiometabolic disease-free life expectancy from age 50

83 The number of cardiometabolic disease-free life-years after age 50 was

84 f any meaningful magnitude in development of cardiometabolic disease.

85 k factors in 5 trials across the spectrum of cardiometabolic disease.

86 nd potentially long-term risk of obesity and cardiometabolic disease.

87 be evaluated further as predictors of future cardiometabolic disease.

88 e regulation and the development of clinical cardiometabolic disease.

89 on and may suggest new approaches to prevent cardiometabolic disease.

90 onal hypoxia to increased risk of developing cardiometabolic disease.

91 ction are associated with sex differences in cardiometabolic disease.

92 tal factors in utero increase future risk of cardiometabolic disease.

93 nderstanding of the genetic underpinnings of cardiometabolic disease.

94 sition and suggest new approaches to prevent cardiometabolic disease.

95 iative networks linking sleep with aging and cardiometabolic disease: individuals who, compared with

96 thylamine N-oxide (TMAO) in the aetiology of cardiometabolic diseases and chronic kidney disease (CKD

97 sociation of mushroom consumption with major cardiometabolic diseases and mediating biomarkers in 2 l

98 sing scientific findings on dietary fats and cardiometabolic diseases have generated debate among sci

99 and mortality and also increases the risk of cardiometabolic diseases in later life for both mother a

100 Review focuses on understanding the rise of cardiometabolic diseases in LMICs, with particular empha

101 tened beverages, are a major risk factor for cardiometabolic diseases including cardiovascular diseas

102 in the United States in which the burden of cardiometabolic diseases remains extremely high.

103 oncommunicable diseases (NCDs), particularly cardiometabolic diseases such as cardiovascular disease,

104 to improve the prevention and management of cardiometabolic diseases through optimization of dietary

105 m urate levels cause gout and correlate with cardiometabolic diseases via poorly understood mechanism

106 comorbidities including psoriatic arthritis, cardiometabolic diseases, and depression.

107 (C17:0), are associated with lower risks of cardiometabolic diseases, and higher dietary intake of O

108 d increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health disorders.

109 een associated with several risk factors for cardiometabolic diseases, evidence for harmful long-term

110 tic pleiotropy in early growth and adulthood cardiometabolic diseases, implying the need for caution

111 mushroom consumption and the aforementioned cardiometabolic diseases, in subgroups of sex, lifestyle

112 The effect of dietary fats on cardiometabolic diseases, including cardiovascular disea

113 ischemic heart disease and potentially other cardiometabolic diseases, including stroke, obesity, and

114 stin, a protein linked with inflammation and cardiometabolic diseases, is one of few proteins for whi

115 n associated with adult risks of obesity and cardiometabolic diseases, like type 2 diabetes and cardi

116 listic assessment of the risk for developing cardiometabolic diseases, offering patients a range of s

117 ly associated with metabolic dysfunction and cardiometabolic diseases, some people with obesity are p

118 emphasize the importance of sRNA research in cardiometabolic diseases, we highlight the success of mi

119 een having an evening diurnal preference and cardiometabolic diseases.

120 may explain the association between PCOS and cardiometabolic diseases.

121 organs, representing various etiologies for cardiometabolic diseases.

122 mportant endocrine organ with a role in many cardiometabolic diseases.

123 s well as LMIC-based responses to counteract cardiometabolic diseases.

124 ht loss and the treatment of obesity-related cardiometabolic diseases.

125 Obesity increases the risk for cardiometabolic diseases.

126 n and on risk factors and clinical events of cardiometabolic diseases.

127 th body mass index (BMI) and obesity-related cardiometabolic diseases.

128 h effects of mushrooms with respect to major cardiometabolic diseases.

129 GFC in adipose tissue, with consequences for cardiometabolic diseases.

130 k factor for type 2 diabetes (T2D) and other cardiometabolic diseases.

131 dairy foods, demonstrates some benefits for cardiometabolic diseases.

132 nd reducing risk for the development of many cardiometabolic diseases.

133 SB consumption contributes to higher risk of cardiometabolic diseases.

134 y for novel sRNA-mediated gene regulation in cardiometabolic diseases.

135 hild, increasing the risk of NAFLD and other cardiometabolic diseases.

136 s are needed to prevent progression to overt cardiometabolic diseases.

137 s for the prevention of diabetes and related cardiometabolic diseases.

138 t in the prevention and/or risk reduction of cardiometabolic disorders for both men and women.

139 Further, the comorbidity of depression and cardiometabolic disorders will be one of the primary cau

140 uman metabolic health and disease, including cardiometabolic disorders, allergic diseases, autoimmune

141 n reported to have increased future risks of cardiometabolic disorders.

142 Four cardiometabolic drivers-abnormal adiposity, dysglycemia,

143 ity that is associated with a higher risk of cardiometabolic dysregulation, has received growing atte

144 ome-based imputation models for discovery of cardiometabolic effect genes in a diverse dataset.

145 al mechanisms responsible for the beneficial cardiometabolic effects of exercise for future study.

146 tes and their changes associate with various cardiometabolic, endocrine, bone- and energy-related com

147 Clinically relevant cardiometabolic endpoints [including flow-mediated dilat

148 HRadjBMI) and examined its associations with cardiometabolic factors by linear regression and Mendeli

149 al cancer, including lifestyle, obesity, and cardiometabolic factors, that should inform public healt

150 Among alleles associated with increased cardiometabolic GWAS risk, approximately half (53%) were

151 Among 2,843 cardiometabolic GWAS signals, 262 colocalized by LD and

152 sociations between public transportation and cardiometabolic health (including adiposity, type 2 diab

153 racial and ethnic diversity, predicts better cardiometabolic health among adolescents of color.

154 as to examine associations of ASB intake and cardiometabolic health among high-risk women with prior

155 mechanisms, obesity contributes to worsened cardiometabolic health and increases rates of cardiovasc

156 dence-based therapeutic targeting to promote cardiometabolic health and mitigate the development and

157 vidence regarding the role of food timing on cardiometabolic health and weight loss in adults.

158 a could not provide evidence that changes in cardiometabolic health biomarkers in relation to MDE res

159 t loss, and also may improve some aspects of cardiometabolic health by lowering blood pressure and in

160 This plan can improve cardiometabolic health by targeting early mechanistic ev

161 snack intakes, had any impact on markers of cardiometabolic health in adults aged 30-70 y at above-a

162 ng, self-esteem, vitality, and biomarkers of cardiometabolic health in favor of the intervention grou

163 wasting in these patients but its effect on cardiometabolic health is unclear.

164 uide preventive measures and improve overall cardiometabolic health so future viral pandemics confer

165 tabolic changes identify pathways central to cardiometabolic health, cardiovascular disease, and long

166 , quality of family life, perinatal history, cardiometabolic health, cognition, and psychopathology h

167 ed to evaluate associations between ASBs and cardiometabolic health, especially among high-risk indiv

168 s of polyunsaturated fatty acids (PUFAs) for cardiometabolic health, n-3 and n-6 PUFAs and their inte

169 reasing awareness of the significant adverse cardiometabolic health-related changes accompanying midl

170 on the relevance of dietary sugar intake for cardiometabolic health.

171 etabolic alterations, which adversely impact cardiometabolic health.

172 eficial effect of being physically active on cardiometabolic health.

173 aternal diet and improve long-term offspring cardiometabolic health.

174 ral anesthesia can impact adversely on fetal cardiometabolic health.

175 that captures aspects of current and future cardiometabolic health.

176 are associated with measures of appetite and cardiometabolic health.

177 ular vulnerabilities and the need to improve cardiometabolic health.

178 or for several chronic diseases with altered cardiometabolic homeostasis.

179 For instance, several cardiometabolic imaging studies have shown that some ind

180 composite measure of depressive symptoms and cardiometabolic indices at 24 months.

181 s of the identified growth trajectories with cardiometabolic markers and body composition at 5 y were

182 timated percentage differences in continuous cardiometabolic markers and RRs for clinical endpoints i

183 tically significant difference in any of the cardiometabolic markers between groups.

184 Fish oil improves cardiometabolic markers in adults, but results in childr

185 lood pressure (coprimary outcomes) and other cardiometabolic markers in healthy Danish children and w

186 and FFM growth with any of the other studied cardiometabolic markers including glucose, HbA1c, insuli

187 metabolism, but not with blood pressure and cardiometabolic markers related to glucose homeostasis.

188 ency questionnaire) with parallel changes in cardiometabolic markers using multiple linear regression

189 a to describe dietary trends and the related cardiometabolic mortality burden in China.

190 y factors, individually and collectively, on cardiometabolic mortality were estimated by calculating

191 al pathways in susceptibility to autoimmune, cardiometabolic, neuropsychiatric, and neoplastic diseas

192 We examined cardiometabolic outcomes at the DWH clinical exam.

193 e preventive strategies focused on improving cardiometabolic outcomes in later life may need to targe

194 nlikely to be a major determinant of adverse cardiometabolic outcomes in population based samples of

195 a beneficial effect of flavan-3-ol intake on cardiometabolic outcomes, but there was considerable het

196 sociations of early-life nutrition and adult cardiometabolic outcomes.

197 D supplementation in early life on long-term cardiometabolic outcomes.

198 parameters (summary effect size: g = 1.19), cardiometabolic parameters (g = 0.23); HPA parameters (g

199 y weight reduction, sustained improvement in cardiometabolic parameters, and a trend toward reduction

200 outcomes included patient-reported outcomes, cardiometabolic parameters, clinical outcomes, and safet

201 s; and associations of changes in SCFAs with cardiometabolic parameters.

202 isk factor contributing to mortality through cardiometabolic pathways.

203 ulation across 12 complex anthropometric and cardiometabolic phenotypes (n = 2,231; observed-to-expec

204 es of microbiome research in CVD and related cardiometabolic phenotypes that have helped to move the

205 ver, there are no data on any effects on the cardiometabolic physiology of the fetus or mother in res

206 These antibodies also improve the cardiometabolic profile of mice and might be developed f

207 adipose tissue (hVAT) associates with a poor cardiometabolic profile.

208 ure of 257 circulating protein biomarkers of cardiometabolic relevance through high-depth (22.5x) who

209 idemiological studies have linked lifestyle, cardiometabolic, reproductive, developmental, and inflam

210 Preterm birth has been associated with cardiometabolic, respiratory, and neuropsychiatric disor

211 id hormone (PTH) can help explain the higher cardiometabolic risk among African Americans is unknown.

212 sufficient to properly assess or manage the cardiometabolic risk associated with increased adiposity

213 iations with body composition and markers of cardiometabolic risk at age 5 y.

214 prolonged sitting has beneficial impacts on cardiometabolic risk biomarkers.

215 arnitine, and betaine) with inflammatory and cardiometabolic risk biomarkers; and 2) to identify feca

216 Efforts to prevent YOD and intensify cardiometabolic risk factor control while focusing on me

217 Exploratory cardiometabolic risk factor responses to a prescribed 25

218 Fat distribution is an independent cardiometabolic risk factor.

219 Although diet response prediction for cardiometabolic risk factors (CRFs) has been demonstrate

220 ntive interventions for diabetes can improve cardiometabolic risk factors (CRFs), but it is unclear w

221 come of MI and ischemic stroke, adjusted for cardiometabolic risk factors (hazard ratio [HR] for quar

222 birthweight associated variants on offspring cardiometabolic risk factors after adjusting for offspri

223 olic fatty liver disease are associated with cardiometabolic risk factors already in childhood.

224 Both chronic cardiometabolic risk factors and genetics have been show

225 we investigated whether associations between cardiometabolic risk factors and prevalent cognitive imp

226 suggest that late eating is associated with cardiometabolic risk factors and reduced efficacy of a w

227 a novel determinant of diagnostic value for cardiometabolic risk factors and suggest Rap1 as a promi

228 Associations between fast build-up and all cardiometabolic risk factors except non-HDL cholesterol

229 esidential surrounding built-up land use and cardiometabolic risk factors in an urbanizing peri-urban

230 causal relation of abdominal adiposity with cardiometabolic risk factors in children by applying Men

231 , increasing evidence highlights the role of cardiometabolic risk factors in determining the suscepti

232 The burden of liver fat and associated cardiometabolic risk factors in healthy children is unkn

233 a high prevalence of all single and combined cardiometabolic risk factors in Nepal.

234 e restriction significantly reduced multiple cardiometabolic risk factors in young, non-obese adults.

235 Cardiometabolic risk factors influence white matter hype

236 Other cardiometabolic risk factors may be differently modified

237 n plasma triglycerides and potentially other cardiometabolic risk factors starting in childhood.

238 esterol concentrations, but effects on other cardiometabolic risk factors such as endothelial functio

239 assessed the burden and correlates of three cardiometabolic risk factors, (hypertension, diabetes, a

240 irthweight is also associated with offspring cardiometabolic risk factors, after controlling for offs

241 iferation/ex-vivo cytokine secretion, plasma cardiometabolic risk factors, and fecal bile acid concen

242 ietary sugar with other carbohydrates affect cardiometabolic risk factors, comparing different interv

243 t, offspring GRS is strongly related to many cardiometabolic risk factors, even after conditioning on

244 line to 2 years of all measured conventional cardiometabolic risk factors, including change scores fo

245 hyperintensities (WMHs) in individuals with cardiometabolic risk factors, interfere with the traject

246 For several cardiometabolic risk factors, values considered within n

247 up land use within 300 m of the home and all cardiometabolic risk factors.

248 ime ambulatory blood pressure (BP) and other cardiometabolic risk factors.

249 % CI: 1.10-2.42), even after controlling for cardiometabolic risk factors.

250 onsistently associated with higher levels of cardiometabolic risk factors.

251 disease in adults, but its causal effect on cardiometabolic risk in children remains unclear.

252 in sensitivity estimator (SPISE) to diagnose cardiometabolic risk in Chilean adolescents.

253 ng reduces functional capacity and increases cardiometabolic risk in chronic disease.

254 igher prevalence of hypertension and greater cardiometabolic risk in older women than older men.

255 th height, waist circumference, FM, FFM, and cardiometabolic risk markers at 5 years using multiple l

256 cy were associated with body composition and cardiometabolic risk markers at 5 years.

257 different doses of a vitamin D supplement on cardiometabolic risk markers in young healthy Swedish ch

258 Cardiometabolic risk markers were analyzed as secondary

259 e linked low vitamin D status to unfavorable cardiometabolic risk markers, but double-blinded vitamin

260 ose, sucrose) with other sugars or starch on cardiometabolic risk markers, including LDL cholesterol,

261 The comorbid cardiometabolic risk of NWCO was also explored.

262 increased fiber intake on the improvement in cardiometabolic risk parameters.

263 ecursors, may contribute to inflammatory and cardiometabolic risk pathways.

264 body mass index, associated with an adverse cardiometabolic risk profile already in childhood.

265 from <0.001 to 0.03), reflecting an adverse cardiometabolic risk profile.

266 Given differences in cardiometabolic risk profiles between women and men with

267 Insulin measurements are not advised for cardiometabolic risk screening in large groups.

268 ent dairy subtypes may differently influence cardiometabolic risk through adiposity and lipid pathway

269 We link methylation to cardiometabolic risk through associations to circulating

270 Helminths may protect against cardiometabolic risk through effects on inflammation and

271 rosis Society and the International Chair on Cardiometabolic Risk Working Group on Visceral Obesity s

272 improvements in clinical markers related to cardiometabolic risk, inflammation, nutrition, and anthr

273 that some dietary flavan-3-ol sources reduce cardiometabolic risk, to our knowledge no review has sys

274 bitual dairy consumption and the pathways to cardiometabolic risk.

275 contribute to increased atherosclerosis and cardiometabolic risk.

276 ot represent a homogeneous group in terms of cardiometabolic risk.

277 ength capacity-may attenuate obesity-related cardiometabolic risk.

278 4x10(-38)), among other pathways relevant to cardiometabolic risk.

279 n of obesity was related to heterogeneity in cardiometabolic risk.

280 The development of obesity and cardiometabolic risks may be established already in earl

281 An emerging model of COVID-related cardiometabolic syndrome encompassing events before, dur

282 id accumulation is observed in patients with cardiometabolic syndrome, including obesity, diabetes, i

283 Of cardiometabolic traits examined for adipose tissue eQTL

284 m exposure with child growth, adiposity, and cardiometabolic traits in 515 mother-child pairs in the

285 m to increase insulin resistance and related cardiometabolic traits in African-ancestry populations.

286 We then tested the association of GReX on 15 cardiometabolic traits including blood lipid levels, bod

287 Cardiometabolic traits were measured at baseline and fol

288 Mediation analyses of colocalized genes and cardiometabolic traits within the 434 individuals provid

289 differences between late and early eaters in cardiometabolic traits, satiety hormones, obesogenic beh

290 s derived from human genetic data related to cardiometabolic traits, then define lncRNA's function an

291 Examining 34 cardiometabolic traits, we show systematic differences i

292 d significant genetic correlations with many cardiometabolic traits, with genetic causality analyses

293 ies, including those for age at menarche and cardiometabolic traits.

294 on, while cross-trait associations highlight cardiometabolic traits.

295 ng the observed pleiotropy between urate and cardiometabolic traits.

296 variants in clinically relevant quantitative cardiometabolic traits.

297 impact during later childhood on growth and cardiometabolic traits.

298 pport MetS as a construct: the clustering of cardiometabolic variables in MetS alters their individua

299 orted but the relationships between specific cardiometabolic variables, WMH load and cognitive perfor

300 /computed tomography imaging and blood-based cardiometabolic was assessed at week 0, 12, and 52.